ICR hails ‘momentous’ recommendation of olaparib for breast and prostate cancer 05 Apr 2023 The Institute of Cancer Research, London, has hailed the ‘life-changing’ decision by NICE to recommend that the targeted drug olaparib can be used for NHS patients with both early-stage breast cancer and prostate cancer. Find out more Show/Hide
Experts call for better cancer tests to tailor treatment 30 Jan 2023 Greater use of cancer tests is the key to tailoring use of new treatments for patients more precisely and so increasing their chances of being recommended for use within the NHS, experts say. Find out more Show/Hide
ICR criticises NICE rejection of olaparib for advanced prostate cancer 06 Sep 2022 The Institute of Cancer Research, London, has expressed disappointment that NICE has confirmed its decision not to recommend olaparib for previously treated, hormone-relapsed metastatic prostate cancer. Find out more Show/Hide
All patients’ cancers should be genetically profiled to improve care, say leading health experts 08 Aug 2022
The ICR responds to NICE’s recommendation not to approve abiraterone as first-line treatment for advanced prostate cancer 15 Jul 2021
ICR welcomes NICE’s decision to reassess abiraterone as first-line treatment for advanced prostate cancer 29 Oct 2020
ICR welcomes approval of immunotherapy for head and neck cancer in Scotland but warns of ‘home nations lottery’ 07 Sep 2020